XERS Xeris Biopharma Holdings, Inc.
Stock · NasdaqGS · United States · Healthcare · US98422E1038
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Xeris Biopharma Holdings, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
15.20 USD
+16.21%
52-week range
5.25 – 15.21
Dividend yield—
Market cap2.8B
NowoTrade score
35 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:27. Information, not advice.
Results
Next results
04 Mar 2027
in 116 days · 08:00 · estimate 0.07
Last results
0.06 vs 0.03 estimated
05 Nov 2026 · Beat +125.0%
Beat the estimate
6 of 12
6 missed · 0 in line · 4 beats in a row
Average surprise
+139.2%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 04 Mar 2027 08:00 | 0.07 | — | — | Upcoming |
| 05 Nov 2026 07:00 | 0.03 | 0.06 | +125.0% | Beat |
| 06 Aug 2026 07:00 | — | — | -172.0% | — |
| 07 May 2026 07:00 | — | 0.01 | +1,592.5% | Beat |
| 02 Mar 2026 07:00 | 0.05 | 0.06 | +33.3% | Beat |
| 06 Nov 2025 07:00 | — | — | -100.0% | — |
| 07 Aug 2025 07:00 | -0.03 | -0.01 | +66.7% | Beat |
| 08 May 2025 07:00 | -0.04 | -0.06 | -50.0% | Miss |
| 06 Mar 2025 07:00 | -0.02 | -0.03 | -50.0% | Miss |
| 08 Nov 2024 07:00 | -0.08 | -0.06 | +21.1% | Beat |
| 08 Aug 2024 07:00 | -0.09 | -0.10 | -6.4% | Miss |
| 09 May 2024 07:00 | -0.11 | -0.14 | -32.1% | Miss |
| 06 Mar 2024 07:00 | -0.09 | -0.10 | -16.3% | Miss |
| 09 Nov 2023 07:00 | -0.10 | -0.09 | +14.3% | Beat |
| 08 Aug 2023 07:00 | -0.11 | -0.14 | -27.3% | Miss |
| 09 May 2023 07:00 | -0.15 | -0.12 | +21.7% | Beat |
| 08 Mar 2023 06:00 | -0.15 | -0.10 | +33.3% | Beat |
| 09 Nov 2022 07:00 | -0.15 | -0.16 | -3.2% | Miss |
| 10 Aug 2022 07:00 | -0.22 | -0.19 | +12.3% | Beat |
| 11 May 2022 07:00 | -0.24 | -0.25 | -4.2% | Miss |
| 11 Mar 2022 07:00 | -0.17 | -0.44 | -164.0% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 291.8M | +43.7% | 554K | 0.2% | 0.00 | +100.0% | 27.9M |
| 2024 | 203.1M | +23.9% | -54.8M | -27.0% | -0.37 | +17.8% | -37.8M |
| 2023 | 163.9M | +48.7% | -62.3M | -38.0% | -0.45 | +35.7% | -49.3M |
| 2022 | 110.2M | — | -94.7M | -85.9% | -0.70 | — | -103.4M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 06 Apr 2023 | 1.83 | 1.93 | 1.79 | 1.89 | 0.00% | 754,500 | |
| 05 Apr 2023 | 1.92 | 2.04 | 1.84 | 1.89 | -2.58% | 1,655,400 | |
| 04 Apr 2023 | 1.82 | 1.94 | 1.79 | 1.94 | +6.59% | 2,192,400 | |
| 03 Apr 2023 | 1.64 | 1.83 | 1.64 | 1.82 | +11.66% | 2,798,500 | |
| 31 Mar 2023 | 1.45 | 1.70 | 1.44 | 1.63 | +11.64% | 2,747,300 | |
| 30 Mar 2023 | 1.42 | 1.49 | 1.36 | 1.46 | +10.61% | 2,596,900 | |
| 29 Mar 2023 | 1.33 | 1.35 | 1.31 | 1.32 | -0.75% | 300,200 | |
| 28 Mar 2023 | 1.26 | 1.35 | 1.26 | 1.33 | +4.72% | 662,900 | |
| 27 Mar 2023 | 1.30 | 1.31 | 1.26 | 1.27 | -0.78% | 312,600 | |
| 24 Mar 2023 | 1.28 | 1.30 | 1.25 | 1.28 | 0.00% | 823,900 | |
| 23 Mar 2023 | 1.32 | 1.35 | 1.26 | 1.28 | -3.03% | 679,600 | |
| 22 Mar 2023 | 1.35 | 1.36 | 1.30 | 1.32 | -1.49% | 577,000 | |
| 21 Mar 2023 | 1.29 | 1.36 | 1.28 | 1.34 | +3.88% | 651,900 | |
| 20 Mar 2023 | 1.34 | 1.34 | 1.26 | 1.29 | -4.44% | 875,400 | |
| 17 Mar 2023 | 1.29 | 1.39 | 1.28 | 1.35 | +3.85% | 1,129,100 | |
| 16 Mar 2023 | 1.30 | 1.32 | 1.27 | 1.30 | 0.00% | 429,800 | |
| 15 Mar 2023 | 1.29 | 1.31 | 1.25 | 1.30 | 0.00% | 547,700 | |
| 14 Mar 2023 | 1.26 | 1.36 | 1.24 | 1.30 | +7.44% | 1,218,800 | |
| 13 Mar 2023 | 1.19 | 1.25 | 1.18 | 1.21 | 0.00% | 783,200 | |
| 10 Mar 2023 | 1.25 | 1.25 | 1.13 | 1.21 | -3.20% | 2,101,700 | |
| 09 Mar 2023 | 1.36 | 1.38 | 1.24 | 1.25 | -7.41% | 1,720,400 | |
| 08 Mar 2023 | 1.51 | 1.52 | 1.32 | 1.35 | -11.76% | 1,930,800 | |
| 07 Mar 2023 | 1.43 | 1.56 | 1.41 | 1.53 | +5.52% | 1,373,500 | |
| 06 Mar 2023 | 1.38 | 1.48 | 1.35 | 1.45 | 0.00% | 749,600 | |
| 03 Mar 2023 | 1.33 | 1.49 | 1.33 | 1.45 | +9.02% | 1,333,500 |
Page 37 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Why Xeris Biopharma Holdings (XERS) Is Up 16.2% And What's Next (opens in a new tab) Simply Wall St. · 07 Nov 2026 19:16
- Is Xeris Biopharma Holdings (XERS) Overpriced After Its Q3 Beat And 2026 Outlook Raise? (opens in a new tab) Simply Wall St. · 07 Nov 2026 18:13
- Xeris Biopharma (XERS) Adds Menassie M. Taddese To Its Board (opens in a new tab) Simply Wall St. · 07 Nov 2026 11:13
- Xeris Biopharma Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 06 Nov 2026 23:14
- Xeris Biopharma Holdings Inc (XERS) (Q3 2026) Earnings Call Highlights: Revenue Surges 44% as ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 21:08
- Oppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21 (opens in a new tab) Benzinga · 06 Nov 2026 13:33
- Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12 (opens in a new tab) Benzinga · 06 Nov 2026 10:28
- HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18 (opens in a new tab) Benzinga · 06 Nov 2026 07:52
- Xeris Biopharma Holdings, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 05 Nov 2026 22:47
- Xeris Biopharma (XERS) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 21:34
- Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 05 Nov 2026 19:44
- XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Q3 Beat and Raised Guidance Point to Stronger 2026 (opens in a new tab) ChartMill · 05 Nov 2026 14:20
- Xeris CEO Sees Recorlev Nearing $1B In Annual Sales 3 To 4 Years Earlier Than Expected – XERS Stock On Track To Hit Over 7-Year Highs (opens in a new tab) Stocktwits · 05 Nov 2026 13:55
- Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue Estimates (opens in a new tab) Zacks · 05 Nov 2026 13:35
- Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (opens in a new tab) Zacks · 05 Nov 2026 13:30
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 13.08 USD
- Market cap
- 2.8B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 11.8 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 2.3 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 0.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only 0.9× the interest
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 57× | Weak | 14.94× |
| Price / book | 56.93× | Weak | 3.81× |
| Price / sales | 7.54× | Weak | 3.19× |
| EV / EBITDA | 48.73× | Weak | 12.63× |
| Free cash flow yield | 1.8% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 87.4% | Good | 58.6% |
| Operating margin | 15.8% | Good | 7.8% |
| Net margin | -1.8% | Weak | 2.8% |
| Return on equity | -27.1% | Weak | 5.7% |
| Return on assets | 7.4% | Good | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 38.3% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 4.63× | Weak | 0.48× |
| Net debt / EBITDA | 1.61× | Fair | 1.58× |
| Interest cover | 0.86× | Weak | 2.76× |
| Current ratio | 2.15× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow XERS and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.